drugset / Trial / NCT04944914
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Phase 3
Recruiting
188 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collabGuangdong Provincial People's Hospital · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |